GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD has a total of 37 patent applications. It increased the IP activity by 57.0%. Its first patent ever was published in 2014. It filed its patents most often in EPO (European Patent Office), China and United States. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are VECTUS BIOSYSTEMS LTD, SYNTHON IP INC and BOEHM MARCUS F.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 7 | |
#2 | China | 6 | |
#3 | United States | 6 | |
#4 | WIPO (World Intellectual Property Organization) | 6 | |
#5 | Australia | 4 | |
#6 | Republic of Korea | 3 | |
#7 | Canada | 2 | |
#8 | Brazil | 1 | |
#9 | Mexico | 1 | |
#10 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds | |
#4 | Organic chemistry methods | |
#5 | Acyclic or carbocyclic compounds | |
#6 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Zhang Nong | 35 |
#2 | Wang Yuguang | 34 |
#3 | Xu Zusheng | 22 |
#4 | Wu Tianzhi | 18 |
#5 | Wang Tinghan | 15 |
#6 | He Min | 14 |
#7 | Sun Qingrui | 8 |
#8 | Zusheng Xu | 2 |
#9 | Tinghan Wang | 2 |
#10 | Nong Zhang | 2 |
Publication | Filing date | Title |
---|---|---|
WO2021052386A1 | Combination of small molecule inhibitor of the pd-1/pd-l1 interaction and anti-pd-1 antibody for treating cancer | |
EP3805229A1 | Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof | |
WO2019128918A1 | Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application | |
EP3594216A1 | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof | |
EP3483142A1 | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof | |
AU2016295594A1 | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof | |
EP3287463A1 | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof |